Predictive role of circulating tumor DNA based molecular residual disease for long-term outcomes in non-small cell lung cancer patients: a meta-analysis
Abstract Purpose To identify the predictive role of circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) for long-term outcomes in non-small cell lung cancer (NSCLC) patients. Methods Several databases were searched. The primary outcome was progression-free survival (PFS), and the se...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-06-01
|
| Series: | World Journal of Surgical Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12957-025-03890-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849691372905299968 |
|---|---|
| author | Siyuan Che Dongliang Yu |
| author_facet | Siyuan Che Dongliang Yu |
| author_sort | Siyuan Che |
| collection | DOAJ |
| description | Abstract Purpose To identify the predictive role of circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) for long-term outcomes in non-small cell lung cancer (NSCLC) patients. Methods Several databases were searched. The primary outcome was progression-free survival (PFS), and the secondary outcomes included overall survival (OS) and cancer-specific survival (CSS). Hazard ratios (HRs) and 95% confidence intervals (CIs) were combined, and subgroup analyses based on the time point of MRD detection (landmark vs. longitudinal) and treatment (surgery vs. chemoradiotherapy) were further performed. Results Ten studies with 1859 cases were included. Pooled results demonstrated that positive ctDNA MRD significantly predicted worse PFS (HR = 11.19, 95% CI: 6.10–20.52, P < 0.001), OS (HR = 6.34, 95% CI: 2.27–17.74, P < 0.001) and CSS (HR = 16.67, 95% CI: 10.00–25.00, P < 0.001). Subgroup analysis by the time points of MRD detection (landmark: HR = 8.93, P < 0.001; longitudinal: HR = 17.52, P < 0.001) and treatment (surgery: HR = 11.63, P < 0.001; chemoradiotherapy: HR = 5.56, P < 0.001) revealed consistent results. Conclusion ctDNA-based MRD could serve as a valuable prognostic indicator in NSCLC, and patients with positive ctDNA-based MRD are at significantly greater risk of recurrence and lower survival. |
| format | Article |
| id | doaj-art-ec10ebb5b80742df84c8a3ebfaf4479b |
| institution | DOAJ |
| issn | 1477-7819 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | BMC |
| record_format | Article |
| series | World Journal of Surgical Oncology |
| spelling | doaj-art-ec10ebb5b80742df84c8a3ebfaf4479b2025-08-20T03:21:02ZengBMCWorld Journal of Surgical Oncology1477-78192025-06-012311810.1186/s12957-025-03890-3Predictive role of circulating tumor DNA based molecular residual disease for long-term outcomes in non-small cell lung cancer patients: a meta-analysisSiyuan Che0Dongliang Yu1Queen Mary College, Medical School of Nanchang UniversityDepartment of Thoracic Surgery, The Second Affiliated Hospital Medical School of Nanchang UniversityAbstract Purpose To identify the predictive role of circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) for long-term outcomes in non-small cell lung cancer (NSCLC) patients. Methods Several databases were searched. The primary outcome was progression-free survival (PFS), and the secondary outcomes included overall survival (OS) and cancer-specific survival (CSS). Hazard ratios (HRs) and 95% confidence intervals (CIs) were combined, and subgroup analyses based on the time point of MRD detection (landmark vs. longitudinal) and treatment (surgery vs. chemoradiotherapy) were further performed. Results Ten studies with 1859 cases were included. Pooled results demonstrated that positive ctDNA MRD significantly predicted worse PFS (HR = 11.19, 95% CI: 6.10–20.52, P < 0.001), OS (HR = 6.34, 95% CI: 2.27–17.74, P < 0.001) and CSS (HR = 16.67, 95% CI: 10.00–25.00, P < 0.001). Subgroup analysis by the time points of MRD detection (landmark: HR = 8.93, P < 0.001; longitudinal: HR = 17.52, P < 0.001) and treatment (surgery: HR = 11.63, P < 0.001; chemoradiotherapy: HR = 5.56, P < 0.001) revealed consistent results. Conclusion ctDNA-based MRD could serve as a valuable prognostic indicator in NSCLC, and patients with positive ctDNA-based MRD are at significantly greater risk of recurrence and lower survival.https://doi.org/10.1186/s12957-025-03890-3Molecular residual diseaseCirculating tumor DNASurvivalNon-small cell lung cancerMeta-analysis |
| spellingShingle | Siyuan Che Dongliang Yu Predictive role of circulating tumor DNA based molecular residual disease for long-term outcomes in non-small cell lung cancer patients: a meta-analysis World Journal of Surgical Oncology Molecular residual disease Circulating tumor DNA Survival Non-small cell lung cancer Meta-analysis |
| title | Predictive role of circulating tumor DNA based molecular residual disease for long-term outcomes in non-small cell lung cancer patients: a meta-analysis |
| title_full | Predictive role of circulating tumor DNA based molecular residual disease for long-term outcomes in non-small cell lung cancer patients: a meta-analysis |
| title_fullStr | Predictive role of circulating tumor DNA based molecular residual disease for long-term outcomes in non-small cell lung cancer patients: a meta-analysis |
| title_full_unstemmed | Predictive role of circulating tumor DNA based molecular residual disease for long-term outcomes in non-small cell lung cancer patients: a meta-analysis |
| title_short | Predictive role of circulating tumor DNA based molecular residual disease for long-term outcomes in non-small cell lung cancer patients: a meta-analysis |
| title_sort | predictive role of circulating tumor dna based molecular residual disease for long term outcomes in non small cell lung cancer patients a meta analysis |
| topic | Molecular residual disease Circulating tumor DNA Survival Non-small cell lung cancer Meta-analysis |
| url | https://doi.org/10.1186/s12957-025-03890-3 |
| work_keys_str_mv | AT siyuanche predictiveroleofcirculatingtumordnabasedmolecularresidualdiseaseforlongtermoutcomesinnonsmallcelllungcancerpatientsametaanalysis AT dongliangyu predictiveroleofcirculatingtumordnabasedmolecularresidualdiseaseforlongtermoutcomesinnonsmallcelllungcancerpatientsametaanalysis |